Trial · NCT04772547
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Primary Pharmacologic Outcome - Absorption | Open Label | Detectable drug level 3h post-administration | 6 | Participants | |
| Primary Pharmacologic Outcome - Absorption | Open Label | Undetectable drug level 3h post-administration | 0 | Participants | |
| Primary Feasibility Outcome - Enrollment and Drug Delivery | Open Label | Vigabatrin administered within 48h of PASE onset | 6 | Participants | |
| Primary Feasibility Outcome - Enrollment and Drug Delivery | Open Label | Vigabatrin not administered within 48h of PASE onset | 0 | Participants | |
| Primary Feasibility Outcome - Participants With Visual Screening for Taurine Levels | Open Label | Taurine levels collected at 0h | 6 | Participants | |
| Primary Feasibility Outcome - Participants With Visual Screening for Taurine Levels | Open Label | Taurine levels collected at 72h | 4 | Participants | |
| Primary Feasibility Outcome - Participants With Visual Screening for Taurine Levels | Open Label | Taurine levels collected at 168h | 1 | Participants | |
| Ultra-early Vigabatrin Administration | Open Label | within 12h of PASE onset | 1 | Participants | |
| Ultra-early Vigabatrin Administration | Open Label | within 12-24h of PASE onset | 3 | Participants | |
| Ultra-early Vigabatrin Administration | Open Label | within 24-48h of PASE onset | 2 | Participants | |
| Secondary Pharmacologic Outcome: Elimination | Open Label | Undetectable vigabatrin concentration at 72h | 2 | Participants | |
| Secondary Pharmacologic Outcome: Elimination | Open Label | Detectable vigabatrin concentration at 72h | 2 | Participants | |
| Secondary Pharmacologic Outcome: Elimination | Open Label | Undetectable vigabatrin concentration at 7 days | 2 | Participants | |
| Secondary Pharmacologic Outcome: Elimination | Open Label | Detectable vigabatrin concentration at 7 days | 0 | Participants | |
| PASE Onset Detection | PASE Onset Misses | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04772547/results